For research use only. Not for therapeutic Use.
Retaspimycin hydrochloride(Cat No.:I005152)is a selective inhibitor of the Hsp90 (heat shock protein 90) chaperone protein, which plays a crucial role in stabilizing and activating various client proteins involved in cancer cell growth and survival. By inhibiting Hsp90, retaspimycin disrupts the function of multiple oncogenic proteins, leading to tumor cell death and inhibition of cancer progression. It has been investigated in clinical trials for the treatment of various cancers, including solid tumors and hematologic malignancies. While promising, further research is needed to determine its safety, efficacy, and potential therapeutic applications in oncology.
Catalog Number | I005152 |
CAS Number | 857402-63-2 |
Synonyms | [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6,20,22-trihydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16-oxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(22),8,12,14,18,20-hexaen-10-yl] carbamate;hydrochloride |
Molecular Formula | C31H46ClN3O8 |
Purity | ≥95% |
Target | Metabolic Enzyme/Protease |
Solubility | 100 mM in H2O |
Storage | Store at -20°C |
IUPAC Name | [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate;hydrochloride |
InChI | InChI=1S/C31H45N3O8.ClH/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35;/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38);1H/b11-9-,18-10+,20-15+;/t17-,19+,24+,25+,27-,29+;/m1./s1 |
InChIKey | OIRUWDYJGMHDHJ-AFXVCOSJSA-N |
SMILES | C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)/C)OC)OC(=O)N)\C)C)O)OC.Cl |